Patient-derived xenograft models
We have partnered with more than 20 cancer clinics to provide access to a wider range of patient-derived xenograft (PDX) cancer models at earlier passage numbers than any other PDX collection available today.
More than 200 unique PDX oncology models from treatment naive and resistant patients have been established in the highly immunodeficient NSG (005557) mouse strain. NSG mice engraft primary human tumors, that after low passage retain the genetic and phenotypic heterogeneity typically seen in human cancers, offering a distinct advantage over other PDX hosts. This preclinical platform can predict the effectiveness of novel therapeutics to treat patients with cancer. We can conduct efficacy testing in any PDX cancer model or distribute tumor-bearing mice to your facility.
PDX LiveTM tumor models
Our collection of readily available, off-the-shelf, PDX tumor engrafted cohorts can help you put mice on study sooner, allowing rapid study turnaround and faster decision-making.
Complete PDX cancer resource
These tumors are available for engraftment in NSG mice for shipment of tumor-bearing mice to your facility or for execution of efficacy studies performed in our facility by our oncology scientists.
PDX resource development
Information on patient clinical history and genomics data sets are available at no cost. Frozen tumor tissue and prepared slides are available for biomarker analysis at a nominal cost.